Prazolok™

Prazosin
Alpha Receptor Blocker (Cardiovascular Preparations)

Indication:

Hypertension (Primary and Secondary Hypertension), Congestive heart failure (Prazosin may be used alone or added to the therapeutic regimen in those patients with congestive heart failure who are resistant or refractory to conventional therapy with diuretics and/or cardiac glycosides), Raynaud’s disease & Benign prostatic hyperplasia (For the symptomatic treatment of urinary obstruction due to BPH and in patients awaiting prostatic surgery).

Dosage & Administration:

Hypertension: 0.5 mg – 20 mg daily. Recommended starting dose is 0.5 mg (in the evening), twice or thrice daily for 3 to 7 days. This dose should be increased to 1 mg twice or three times daily for a further 3 to 7 days. Maximum dose: 20 mg in divided doses. Patients receiving other antihypertensive therapy but with inadequate control: The dose of the other drug should be reduced to a maintenance level and Prazosin initiated at o.5 mg in the evening, then continuing with o.5 mg twice or three times daily.

Congestive heart failure: The recommended starting dose is 0.5 mg two, three or four times daily, increasing to 4 mg in divided doses. Usual daily maintenance dose: 4 mg to 20 mg in divided doses.

Raynaud’s disease: The recommended starting dose is 0.5 mg twice daily given for a period of 3 to 7 days and should be adjusted according to the patient’s clinical response. Usual maintenance dose is 1 mg or 2 mg twice daily.

Benign prostatic hyperplasia: The recommended dose is 0.5 mg twice daily for a period of 3 to 7 days, with the initial dose administered in the evening. The usual maintenance dose is 2 mg twice daily.

Preparation:

Prazolok™ 1: Each box contains 30 tablets in blister pack.
Prazolok™ 2: Each box contains 30 tablets in blister pack.